Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy

This study has been terminated.

(This study was stopped because of an inadequate rate of enrollment.)

Sponsor:

Information provided by:

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

ClinicalTrials.gov Identifier:

NCT00083434

First received: May 24, 2004

Last updated: April 25, 2011

Last verified: April 2011

History of Changes

Tracking Information
First Received Date ^ICMJE	May 24, 2004
Last Updated Date	April 25, 2011
Start Date ^ICMJE	February 2004
Primary Completion Date	Not Provided
Current Primary Outcome Measures ^ICMJE	Not Provided
Original Primary Outcome Measures ^ICMJE	Not Provided
Change History	Complete list of historical versions of study NCT00083434 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^ICMJE	Not Provided
Original Secondary Outcome Measures ^ICMJE	Not Provided
Current Other Outcome Measures ^ICMJE	Not Provided
Original Other Outcome Measures ^ICMJE	Not Provided

Descriptive Information
Brief Title ^ICMJE	Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy
Official Title ^ICMJE	Not Provided
Brief Summary	The purpose of this study is to examine the effectiveness of epoetin alfa in treating anemia in patients who have cancer or who no longer have any signs of the cancer, but remain anemic as a result of their treatment.
Detailed Description	Not Provided
Study Type ^ICMJE	Interventional
Study Phase	Phase 3
Study Design ^ICMJE	Endpoint Classification: Efficacy Study Primary Purpose: Treatment
Condition ^ICMJE	Anemia Cancer
Intervention ^ICMJE	Drug: Epoetin alfa
Study Arm (s)	Not Provided
Publications *	Not Provided
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Terminated
Enrollment ^ICMJE	Not Provided
Completion Date	October 2004
Primary Completion Date	Not Provided
Eligibility Criteria ^ICMJE	Inclusion Criteria: 18 years of age or older Body weight >/= 99lbs ECOG 0-2 Anemia results from cancer, chemotherapy, radiotherapy or an association with hormonal therapy or immunotherapy Screening hemoglobin level of </= 11.0 g/dL for men or </= 10.0 for women Exclusion Criteria: History of or concurrent second malignancy Evidence of primary or metastatic malignancy involving the Central Nervous System
Gender	Both
Ages	18 Years and older
Accepts Healthy Volunteers	No
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE	United States

Administrative Information
NCT Number ^ICMJE	NCT00083434
Other Study ID Numbers ^ICMJE	CR010549, EPO-CAN-303
Has Data Monitoring Committee	Yes
Responsible Party	Not Provided
Study Sponsor ^ICMJE	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Collaborators ^ICMJE	Not Provided
Investigators ^ICMJE	Not Provided
Information Provided By	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Verification Date	April 2011
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top